Eli Lilly said on Monday it would buy Loxo Oncology for about $8 billion in cash, buying into a portfolio of targeted medicines to treat cancers causedThe offer of $235 per share in cash represents a premium of about 68 percent to Loxo's Friday close. Loxo's shares surged 32.8 percent to $185.70 in light trading before the bell, while those of Lilly dropped 2.7 percent to $111.60.
